A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma

Zeng, XH; Jia, YX; Chen, HM; Luo, QL; Zhao, HK; Liang, GZ; Chen, W; Li, YS

Chen, W; Li, YS (通讯作者)，Chongqing Univ, Canc Hosp, Dept Med Oncol, Chongqing 400030, Peoples R China.;Chen, W; Li, YS (通讯作者)，Chongqing Canc Inst, Chongqing 400030, Peoples R China.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023; 149 (11): 9213

Abstract

PurposeProgrammed death-1 (PD-1) inhibitor sintilimab plus bevacizumab has been approved as the first-line treatment for patients with advanced hepato......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索